I strongly believe that this will be a signal to the market. Often, a Form EFFECT before a strategic announcement, signals that the company is tidying up regulatory loose ends ahead of a larger move or preparing to be “transaction ready.”

Big Pharma will not enter a buyout or partnership unless the SEC and market compliance issues are fully cleared.

If we are indeed in talks with a large pharma (of which I believe we have been for quite some time) This filing does not mean a partnership/buyout will happen, but it removes one of the big hurdles. It also positions CytoDyn to say: “Our securities are clean, registered, and tradeable. We’re ready for institutional interest or acquisition.”

Bottom line this filing is extremely important. It strengthens CytoDyn’s negotiating position and makes the company more attractive for a partnership or buyout, because it clears up share registration, improves liquidity, and potentially boosts funding flexibility.